Nkgen Biotech Inc (NKGN)

Überblick Nachrichten Preisverlauf Warum fällt NKGN? Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Nkgen Biotech Inc Stock (NKGN) Company Profile

Nkgen Biotech Inc

Healthcare (1064)

Biotechnology (595)

Nächster Verdiensttermin

Neueste SEC-Einreichungen

NKGN's Discussions on Twitter

Compare NKGN vs VRTX, MRNA, REGN, ARGX, RVMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NKGN Nkgen Biotech Inc	0.0021	0	3,000	-23.55M	-19.75M	-1.2183
VRTX Vertex Pharmaceuticals Inc	504.73	127.93B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	190.01	79.40B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	735.20	81.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	919.21	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	206.64	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Nkgen Biotech Inc Aktie (NKGN) Neueste Nachrichten

Finanzdaten der Nkgen Biotech Inc-Aktie (NKGN)

Nkgen Biotech Inc (NKGN)

Nkgen Biotech Inc Stock (NKGN) Company Profile

Compare NKGN vs VRTX, MRNA, REGN, ARGX, RVMD

Nkgen Biotech Inc Aktie (NKGN) Neueste Nachrichten

NKGen Biotech to Present on Troculeucel for - GlobeNewswire

NKGen Biotech to Present on Potential of Troculeucel in - GlobeNewswire

NKGen Biotech Expands Financing Through Convertible Note Issuance - TipRanks

NKGen Biotech Korea Co., Ltd. Revenue Breakdown – KRX:182400 - TradingView

NKGen Biotech Inc. Revenue Breakdown – OTC:NKGNW - TradingView

NKGen Biotech Inc. Revenue Breakdown – OTC:NKGN - TradingView

Price to earnings forward of NKGen Biotech Inc. – OTC:NKGN - TradingView

Price to sales forward of NKGen Biotech Inc. – OTC:NKGN - TradingView

Enterprise value to revenue forward of NKGen Biotech Inc. – OTC:NKGN - TradingView

Price to book forward of NKGen Biotech Inc. – OTC:NKGN - TradingView

NKGen Biotech Amends Term Loan and Collateral Agreement - TipRanks

NKGen Biotech (NKGN) alters collateral on $5M credit facility - Stock Titan

Enterprise value to revenue forward of NKGen Biotech Inc. – OTC:NKGNW - TradingView

Price to book forward of NKGen Biotech Inc. – OTC:NKGNW - TradingView

Price to earnings forward of NKGen Biotech Inc. – OTC:NKGNW - TradingView

Number of employees of NKGen Biotech Inc. – OTC:NKGNW - TradingView

Price to sales forward of NKGen Biotech Korea Co., Ltd. – KRX:182400 - TradingView

NKGen Biotech takes Alzheimer’s research global - Longevity.Technology

Price to earnings forward of NKGen Biotech Korea Co., Ltd. – KRX:182400 - TradingView

Enterprise value to revenue forward of NKGen Biotech Korea Co., Ltd. – KRX:182400 - TradingView

NKGen Biotech announces new funding to regain compliance with reporting obligations and listing standards - MSN

NKGen Biotech to present Alzheimer’s drug trocu... - Pluang

NKGen's CEO to Present Alzheimer’s Cell Therapy at Seoul Forum - Stock Titan

NKGen Biotech to Present at the 2026 BIOCHINA Global Forum - GlobeNewswire

Alzheimer’s Disease Pipeline Accelerates as 200+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com

NKGen Biotech Expands Convertible Financing Through New Agreement - The Globe and Mail

NKGen Biotech (NKGN) takes $2.42M note, lifts consideration shares - Stock Titan

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga

A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - PR Newswire

NKGen Biotech Expands Financing Through New Convertible Loan - TipRanks

NKGen Biotech (NKGN) expands AlpineBrook convertible deal with $412.5K note and new warrant - Stock Titan

Nkgen Biotech expands clinical trial site network for Alzheimer’s disease program across US - marketscreener.com

Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US - TradingView

NKGen Biotech Inc. is expanding its Alzheimer’s disease clinical trial site network nationwide across the United States. - Bitget

NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’s Disease Program Across U.S. to Improve Patient Access and Support Enrollment - marketscreener.com

New Alzheimer’s trial sites move NK cell therapy closer to East Coast patients - Stock Titan

NKGen Biotech Expands Clinical Trial Site Network for - GlobeNewswire

Number of shareholders of NKGen Biotech Inc. – OTC:NKGN - TradingView

NKGen Biotech Secures Additional Convertible Financing and Warrants - TipRanks

NKGen Biotech (NKGN) expands dilutive note deal with 12M+ shares, warrant - Stock Titan

NKGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan

NKGen Biotech Announces Major Convertible Financing and Governance Shift - TipRanks

NKGen Biotech (NKGN) inks $39,922,134.22 secured convertible loan and control rights - Stock Titan

NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit - marketscreener.com

NKGen Biotech to Present Troculeucel Mechanism Data in - GlobeNewswire

Former Bio Firm Executive Charged for Insider Trading on Drug Approval Tip - Seoul Economic Daily

NKGen Biotech Reports Combined Phase 1 Troculeucel Data - GlobeNewswire

Troculeucel Linked to Plasma GFAP Changes and Cognitive Measures in Early Alzheimer Disease Studies - NeurologyLive

Troculeucel may boost cognition, new Alzheimer’s data shows - Longevity.Technology

NKGen Biotech to Present Integrated Phase 1 Clinical and - GlobeNewswire

Nkgen Biotech amends loan agreement to secure additional $343,000 funding - Investing.com

Finanzdaten der Nkgen Biotech Inc-Aktie (NKGN)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie NKGN